Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab ; volume:8 ; number:1 ; day:25 ; month:11 ; year:2010 ; pages:1 ; date:11.2010
Journal of translational medicine ; 8, Heft 1 (25.11.2010), 1, 11.2010
- Creator
-
Morales-Lara, M J.
- Contributor
-
Conesa-Zamora, P.
Santaclara, V.
Torres-Moreno, D.
Pedrero, F.
Moreno-Morales, J.
Cogolludo, V.
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-8-S1-P51
- URN
-
urn:nbn:de:1111-2016041436079
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Morales-Lara, M J.
- Conesa-Zamora, P.
- Santaclara, V.
- Torres-Moreno, D.
- Pedrero, F.
- Moreno-Morales, J.
- Cogolludo, V.
- SpringerLink (Online service)
Other Objects (12)
Body mass index influences the response to infliximab in ankylosing spondylitis
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
HLA-E gene polymorphism associates with ankylosing spondylitis in Sardinia
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Andersson lesion in ankylosing spondylitis
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
T cell responses to putative antigens and downregulation of cytokineproduction by infliximab in ankylosing spondylitis patients
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study
T-cell response to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
T-cell responses to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
Body mass index influences the response to infliximab in ankylosing spondylitis
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
HLA-E gene polymorphism associates with ankylosing spondylitis in Sardinia
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Andersson lesion in ankylosing spondylitis
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
T cell responses to putative antigens and downregulation of cytokineproduction by infliximab in ankylosing spondylitis patients
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study
T-cell response to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
T-cell responses to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
Body mass index influences the response to infliximab in ankylosing spondylitis
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
HLA-E gene polymorphism associates with ankylosing spondylitis in Sardinia
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Andersson lesion in ankylosing spondylitis
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
T cell responses to putative antigens and downregulation of cytokineproduction by infliximab in ankylosing spondylitis patients
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study
T-cell response to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients